Synlogic, Inc.

SYBX Healthcare Biotechnology

Synlogic, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8,000.00, down 99.8% from fiscal 2023. In the quarter to June 2026, EPS was flat and free cash flow fell 277.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.00 0.08 −7.41%
Market cap
$6.7M
P/E
0.0×
Fwd P/E
−2.8×
Dividend yield
—
F-score
3/9
Altman Z
−35.79
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
9.02 6.86 4.09 2.50
Current Ratio
9.19 7.08 4.30 2.65
Net Debt/EBITDA
13.03 10.69 10.93 15.73
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
1.70 (0.83) (0.61) 0.62
Capex/Depreciation
— — 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.07) (0.05) (0.07) (0.12)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.07) (0.05) (0.07) (0.12)
Cash per Share
1.06 1.14 1.19 1.27
Shareholders Equity per Share
0.97 1.01 0.96 0.84
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
0.97 1.01 0.96 0.84
Free Cash Flow
(0.92) (0.56) (0.92) (1.44)
Working Capital
11.97 12.50 11.81 10.28
Capital Expenditures
— — 0.00 0.00
Net Current Asset Value
11.97 12.50 11.81 10.28
EV/EBIT
— — — —
Capex to Sales
— — 0.00 0.00
Other line items
Average Payables
0.06 0.14 0.13 0.14
Average Assets
15.42 16.29 17.64 18.66
Average Common Equity
12.31 12.82 12.31 11.72

Fold the line items

Columns are period end dates